Advertisement

Drugs

, Volume 42, Issue 5, pp 781–795 | Cite as

Cyclophosphamide Toxicity

Characterising and Avoiding the Problem
  • Lucy H. Fraiser
  • Sarathchandra Kanekal
  • James P. Kehrer
Practical Therapeutic

Summary

Cyclophosphamide, an orally active alkylating agent, is widely used to treat a variety of malignant and nonmalignant disorders. Although it has some tumour selectivity, it also possesses a wide spectrum of toxicities. The requirement of metabolic activation before cyclophosphamide exerts either its therapeutic or toxic effects is well established, but has not led to effective countermeasures. Clinically, damage to the bladder (haemorrhagic cystitis), immunosuppression (when not desired) and alopecia are the most significant toxicities associated with cyclophosphamide. Cardiotoxicity is also a possibility when very high doses are given. Preventing these toxicities has focused on modifications of the treatment regimens and, in the case of haemorrhagic cystitis, the administration of a drug which is excreted in the urine where it inactivates the bladder-toxic species. As treatment regimens for cancer become more effective in prolonging a patient’s life, and as cyclophosphamide receives increasing use for nonmalignant disorders, the potential for cyclophosphamide-induced cancers, particularly in the bladder, must be recognised. Although the toxicities associated with cyclophosphamide are serious, this agent remains a highly effective drug in many situations. Research on the pathways which play an important role in activating this drug may improve our ability to target particular diseases and decrease unwanted side effects.

Keywords

Cyclophosphamide Cystitis Acrolein Pulmonary Toxicity Mesna 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdel Karim FW, Ayash RE, Allam C, Salem PA. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide: a case report. Oncology 40: 174–176, 1983PubMedCrossRefGoogle Scholar
  2. Adamson IYR. Drug induced pulmonary fibrosis. Environmental Health Perspectives 55: 25–36, 1984PubMedCrossRefGoogle Scholar
  3. Andre R, Rochant H, Dreyfus B, Duhamel G, Pecheri J. Fibrose interstitielle diffuse du poumon au cours d’une maladie de Hodgkin traitee par des doses élevées d’Endoxan. Bulletin de la Societé Medical L’Hopital Paris 118: 1133–1141, 1967Google Scholar
  4. Andriole GL, Yuan JJ, Catalona WJ. Cystotomy, temporary urinary diversion and bladder packing in the management of severe cyclophosphamide-induced hemorrhagic cystitis. Journal of Urology 143: 1006–1007, 1990PubMedGoogle Scholar
  5. Baello EB, Eansberg ME, Ferguson DW, Kugler JW, Gingrich JO, et al. Effect of high-dose cyclophosphamide and total-body irradiation on left ventricular function in adult patients with leukemia undergoing allogenic bone marrow transplantation. Cancer Treatment Reports 70: 1187–1193, 1986PubMedGoogle Scholar
  6. Ballow JE, Austin HA, Muenz LR, et al. Effect of treatment on the evaluation of renal abnormalities in lupus nephritis. New England Journal of Medicine 311: 491–495, 1984CrossRefGoogle Scholar
  7. Beelen DW, Quabeck K, Graeven U, Sayer HG, Mahmoud HK, et al. Acute toxicity and first clinical results of intensive post-induction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 74: 1507–1516, 1989PubMedGoogle Scholar
  8. Bourscaux F, Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B518-ASTA) in experimental tumours in the rat. Nature 181: 931, 1958Google Scholar
  9. Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, et al. High-dose cyclophosphamide therapy for malignant disease: toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29: 357–365, 1972CrossRefGoogle Scholar
  10. Burke DA, Stoddart JC, Ward MK, Simpson CGB. Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide. British Medical Journal 285: 696, 1982PubMedCrossRefGoogle Scholar
  11. Calabresi P, Chabner BA. Chemotherapy of neoplastic diseases. In Gilman et al. (Eds) The pharmacological basis of therapeutics, 8th ed., pp. 1202–1263, MacMillan, New York, 1990Google Scholar
  12. Case Records of the Massachusetts General Hospital (Case 26-1972). New England Journal of Medicine 286: 1405-1411, 1972Google Scholar
  13. Cazin B, Gorin C, Laprote P, Gallet B, Douay L, et al. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer 57: 2061–2069, 1986PubMedCrossRefGoogle Scholar
  14. Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. In Perry MC & Yarbro JW (Eds) Toxicity of chemotherapy, pp. 343–363, Grune & Stratton, Orlando, 1984Google Scholar
  15. Chaube S, Kurg G, Murphy ML. Teratogenic effects of cyclophosphamide (NSC-26271) in the rat. Cancer Chemotherapy Reports 51: 363–376, 1967Google Scholar
  16. Cooper AJD, White DA, Matthay RA. Drug-induced pulmonary disease. American Review of Respiratory Disease 133: 321–340, 1986PubMedGoogle Scholar
  17. Cox PJ. Cyclophosphamide cystitis and bladder cancer: a hypothesis. European Journal of Cancer 15: 1071–1072, 1979bPubMedCrossRefGoogle Scholar
  18. Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochemical Pharmacology 28: 2045–2049, 1979aPubMedCrossRefGoogle Scholar
  19. Cupps TR. Cyclophosphamide: to pulse or not to pulse? American Journal of Medicine 89: 399–402, 1990PubMedCrossRefGoogle Scholar
  20. DeFronzo RA, Braine H, Colvin M. Water intoxication in man after cyclophosphamide therapy: time course and relation to drug activation. Annals of Internal Medicine 78: 861–869, 1973Google Scholar
  21. DeVries CR, Freiha FS. Hemorrhagic cystitis: a review. Journal of Urology 143: 1–7, 1990Google Scholar
  22. Dohner VA, Ward HP, Standard RE. Alveolitis during procar-bazine, vincristine and cyclophosphamide therapy. Chest 62: 636–639, 1972PubMedCrossRefGoogle Scholar
  23. Dorr RT, Fritz WL (Eds). Cancer chemotherapy handbook, El-sevier, New York, 1980Google Scholar
  24. Efros M, Ahmed T, Choudhury M. Cyclophosphamide-induced hemorrhagic pyelitis and ureteritis associated with cystitis in marrow transplantation. Journal of Urology 144: 1231–1232, 1990PubMedGoogle Scholar
  25. Eigner EB, Freiha FS. The fate of the remaining bladder following supravesical diversion. Journal of Urology 144: 31–33, 1990PubMedGoogle Scholar
  26. Fairchild WV, Spence CR, Solomon HD, Gangai MP. The incidence of bladder cancer after cyclophosphamide therapy. Journal of Urology 122: 163–164, 1979PubMedGoogle Scholar
  27. Forni AM, Koss LG, Geller W. Cytological study of the effect of cyclophosphamide on the epithelium of the urinary bladder in man. Cancer 17: 1348–1355, 1964PubMedCrossRefGoogle Scholar
  28. Gershwin ME, Goetzl EJ, Steinberg AD. Cyclophosphamide: use in practice. Annals of Internal Medicine 80: 531–540, 1974PubMedGoogle Scholar
  29. Gould VE, Miller J. Sclerosing alveolitis induced by cyclophosphamide. American Journal of Pathology 81: 513–528, 1975PubMedGoogle Scholar
  30. Grinberg-Funes D, Sheldon C, Weiss M. The use of prostaglandin F2alpha for the prophylaxis of cyclophosphamide induced cystitis in rats. Journal of Urology 144: 1500–1504, 1990PubMedGoogle Scholar
  31. Gurtoo HL, Hipkens JH, Sharma SD. Role of glutathione metabolism dependent toxicity and chemotherapy of cyclophosphamide. Cancer Research 41: 3584–3591, 1981PubMedGoogle Scholar
  32. Hakkinen PJ, Whiteley JW, Witschi HP. Hyperoxia, but not thoracic X-radiation, potentiates bleomycin and cyclophosphamide-induced lung damage in mice. American Review of Respiratory Disease 126: 281–285, 1982PubMedGoogle Scholar
  33. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. American Journal of Medicine 89: 403–410, 1990PubMedCrossRefGoogle Scholar
  34. Hopkins HA, Betsill WL, Hobson AS, Looney WB. Cyclophosphamide induced cardiomyopathy in the rat. Cancer Treatment Reports 66: 1521–1527, 1982PubMedGoogle Scholar
  35. Horn M, Phebus C, Blatt J. Cancer chemotherapy after solid organ transplantation. Cancer 66: 1468–1471, 1990PubMedCrossRefGoogle Scholar
  36. Johnson WW, Meadows DC. Urinary-bladder fibrosis and telangiectasia associated with long term cyclophosphamide therapy. New England Journal of Medicine 284: 290–294, 1971PubMedCrossRefGoogle Scholar
  37. Karnofsky DA. Late effects of immunosuppressive anticancer drugs. Federation Proceedings 26: 925–932, 1967PubMedGoogle Scholar
  38. Kaye CM. Biosynthesis of mercapturic acids from allyl alcohol, allyl esters and acrolein. Biochemical Journal 134: 1093–1101, 1973PubMedGoogle Scholar
  39. Kehrer JP, Klein-Szanto AJP, Sorensen EMB, Pearlman R, Rosner MH. Enhanced acute lung damage following corticosteroid treatment. American Review of Respiratory Disease 130: 256–261, 1984PubMedGoogle Scholar
  40. Koss LG. A light and electron microscopic study of the effect of a single dose of cyclophosphamide on various organs in the rat. Laboratory Investigation 16: 44–65, 1967PubMedGoogle Scholar
  41. Lawrence HJ, Simone J, Aur JA. Cyclophosphamide-induced hemorrhagic cystitis in children with leukemia. Cancer 36: 1572–1576, 1975PubMedCrossRefGoogle Scholar
  42. Lazo JS, Hoyt DG. The molecular basis of interstitial pulmonary fibrosis by antineoplastic agents. Cancer Treatment Reviews 17: 165–167, 1990PubMedCrossRefGoogle Scholar
  43. Lee Y-CC, Kehrer JP. Increased pulmonary collagen syntheses in mice treated with cyclophosphamide. Drug and Chemical Toxicology 8: 503–512, 1985PubMedCrossRefGoogle Scholar
  44. Lemmers MJ, Barry JM. Denovo carcinoma of the lower urinary tract in renal allograft recipients. Journal of Urology 144: 1233–1235, 1990PubMedGoogle Scholar
  45. Levine LA. Kranc DM. Evaluation of carboprost tromethamine in the treatment of cyclophosphamide-induced hemorrhagic cystitis. Cancer 66: 242–245, 1990Google Scholar
  46. Levine LA. Richie JP. Urological complications of cyclophosphamide. Journal of Urology 141: 1063–1069, 1989Google Scholar
  47. Mark GJ, Lehimgar-zadeh A, Ragsdale BD. Cyclophosphamide pneumonitis. Thorax 33: 89–93, 1978PubMedCrossRefGoogle Scholar
  48. Mathé G. Prevention of chemotherapy complications: time, toxicity, pharmacokinetic, pharmacodynamic and logistic factors. In Mathé and Oldham (Eds) Complications of cancer chemotherapy, pp. 124–139, Springer-Verlag, New York, 1974CrossRefGoogle Scholar
  49. Maxwell I. Reversible pulmonary edema following cyclophosphamide treatment. Journal of the American Medical Association 229: 137–138, 1974PubMedCrossRefGoogle Scholar
  50. McDougal WS, Cramer SF, Miller R. Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease. Cancer 48: 691–695, 1981PubMedCrossRefGoogle Scholar
  51. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature. Cancer 43: 2223–2226, 1979PubMedCrossRefGoogle Scholar
  52. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapeutic agents. In Yarbro et al. (Eds) Toxicity of chemotherapy, pp. 269–295, Grune & Stratton, New York, 1984Google Scholar
  53. Newell DR, Gore ME. Toxicity of alkylating agents: clinical characteristics and pharmacokinetic determinants. In Powis G & Hacker MP (Eds) Toxicity of anticancer drugs, pp. 44–62, Pergamon Press, New York, 1991Google Scholar
  54. O’Connell TX, Berenbaum MC. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Research 34: 1586–1591, 1974PubMedGoogle Scholar
  55. Patel AR, Shah PC, Rhee HL, Sassoon H, Rao KP. Cyclophosphamide therapy and interstitial pulmonary fibrosis. Cancer 38: 1542–1549, 1976PubMedCrossRefGoogle Scholar
  56. Patel JM, Block ER, Hood CI. Biochemical indices of cyclophosphamide-induced lung toxicity. Toxicology and Applied Pharmacology 76: 128–138, 1984PubMedCrossRefGoogle Scholar
  57. Patel JM. Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacology and Therapeutics 47: 137–146, 1990PubMedCrossRefGoogle Scholar
  58. Pearlman CK. Cystitis due to cytoxan-Case report. Journal of Urology 95: 713–715, 1966PubMedGoogle Scholar
  59. Pesce A, Cassuto JP, Joyner MV, Path MRC, DuJardin P, et al. Scalp tourniquet in the prevention of chemotherapy-induced alopecia. New England Journal of Medicine 298: 1204–1205, 1978PubMedGoogle Scholar
  60. Phillips FS, Sternberg SS, Cronin AP, Vidal PM. Cyclophosphamide and urinary bladder toxicity. Cancer Research 21: 1577–1589, 1961Google Scholar
  61. Plotz PH, Klippel JH, Decker JL, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Annals of Internal Medicine 91: 221–223, 1979PubMedGoogle Scholar
  62. Plowchalk DR, Mattison DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicology and Applied Pharmacology 107: 472–481, 1991PubMedCrossRefGoogle Scholar
  63. Primack A. Amelioration of cyclophosphamide-induced cystitis. Journal of the National Cancer Institute 47: 223–227, 1971PubMedGoogle Scholar
  64. Rodin AE, Haggard ME, Travis LB. Lung changes and chemotherapeutic agents in childhood. American Journal of Diseases in Children 120: 337–340, 1970Google Scholar
  65. Rubin JS, Rubin RT. Cyclophosphamide hemorrhagic cystitis. Journal of Urology 96: 313–316, 1966PubMedGoogle Scholar
  66. Santos GW, Sensenbrenner L, Burke PJ, Colvin M, Ownen Jr AH, et al. Marrow transplantation in man following cyclophosphamide. Transplantation Proceedings 3: 400–404, 1971PubMedGoogle Scholar
  67. Sen RP, Walsh TE, Fisher W, Brock N. Pulmonary complications of combination therapy with cyclophosphamide and predni- sone. Chest 99: 143–146, 1991PubMedCrossRefGoogle Scholar
  68. Siemann DW, Macler L, Penney DP. Cyclophosphamide-induced pulmonary toxicity. British Journal of Cancer 53 (Suppl. VII): 343–346, 1986Google Scholar
  69. Smith RD, Kehrer JP. Cooxidation of cyclophosphamide as an alternative pathway for its bioactivation and lung toxicity. Cancer Research 51: 542–548, 1991PubMedGoogle Scholar
  70. Spector IJ, Zimbler H, Ross JS. Cyclophosphamide and interstitial pneumonitis. Journal of the American Medical Association 243: 1133, 1980PubMedCrossRefGoogle Scholar
  71. Spector IJ, Zimbler H, Ross JS. Early onset of cyclophosphamide-induced interstitial pneumonitis. Journal of the American Medical Association 242: 2852–2853, 1979PubMedCrossRefGoogle Scholar
  72. Stella F, Battistelli S, Marcheggiani F, De Santis M, Giardini C, et al. Urothelial cell changes due to busulfan and cyclophosphamide treatment in bone marrow transplantation. Acta Cytologica 34: 885–890, 1990PubMedGoogle Scholar
  73. Stillwell TJ, Benson RC. Cyclophosphamide-induced hemorrhagic cystitis. Cancer 61: 451–457, 1988PubMedCrossRefGoogle Scholar
  74. Thrasher JB, Miller GJ, Wettlaufer JN. Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. Journal of Urology 143: 119–121, 1990PubMedGoogle Scholar
  75. Tokaz LK, Von Hoff DD. The cardiotoxicity of anticancer agents. In Yarbro et al. (Eds) Toxicity of chemotherapy, pp. 199–226, Grune & Station Inc, New York, 1984Google Scholar
  76. Toledo TM, Harper RC, Mosser RH. Fetal effects during cyclophosphamide and irradiation therapy. Annals of Internal Medicine 74: 87–91, 1971PubMedGoogle Scholar
  77. Topilow AA, Rothenberg SP, Cottrell TS. Interstitial pneumonia after prolonged treatment with cyclophosphamide. American Review of Respiratory Disease 108: 114–117, 1973PubMedGoogle Scholar
  78. Ziegler JL, Morrow RH, Fass L, et al. Treatment of Burkitt’s tumor with cyclophosphamide. Cancer 26: 474–484, 1970PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Lucy H. Fraiser
    • 1
  • Sarathchandra Kanekal
    • 1
  • James P. Kehrer
    • 1
  1. 1.Division of Pharmacology and Toxicology, College of PharmacyThe University of Texas at AustinAustinUSA

Personalised recommendations